The Bromelain Supplement market is further differentiated by product type, each reflecting distinct manufacturing processes and regulatory pathways. Powdered bromelain—often derived from pineapple stem—dominates the category, representing roughly 60 % of unit volume due to its versatility in capsule, tablet, and functional‑food applications. Its low cost and high enzyme activity make it the preferred choice for bulk manufacturers. Encapsulated bromelain accounts for about 25 % of revenue; this form employs enteric coating to protect the enzyme from gastric acidity, thereby enhancing bioavailability for therapeutic uses. The higher processing expense translates into premium pricing, supporting its prevalence in clinical‑grade supplements. Liquid bromelain formulations, comprising approximately 10 % of the market, target niche segments such as sports drinks and topical gels, where rapid absorption is valued. Finally, Hybrid blends—combinations of bromelain with complementary enzymes (e.g., papain, protease) or phytochemicals—contribute the remaining 5 % and are marketed as comprehensive digestive or anti‑inflammatory solutions. These type‑based distinctions shape the overall market structure, influencing cost structures, distribution channels, and competitive dynamics within the Bromelain Supplement market.
